Pediatric Cell Therapy

Department of Pediatric Cell Therapy.
Research Institute for Oncology, Hematology & Cell Therapy (RIOHCT).
Tehran University of Medical Sciences (TUMS).

[Frontiers - Immunology @FrontImmunol]

New Research: Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease: Chronic graft-versus-host disease (cGVHD) remains a frequent cause of… https://t.co/luvbbqJYn7 #immunology

[TransplantID Journal @TheTxIDjournal]

In a retrospective study from 🇫🇮 of allo-HCT recipients, 59% of all and 77% of R+ patients had CMV infection. CMV infection was associated with longer hospital readmission: median 27 vs 14 days - an overall increase in use of hospital resources #CMV #TxID https://t.co/JDUrjtRcDx

[Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx @CARTTherapy]

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial https://t.co/NMoAw2UrCj

[Blood Advances @BloodAdvances]

Early use of third-party virus-specific T-cells is safe and leads to high rates of viral control and excellent outcomes in HSCT. https://t.co/NPWkBX20Nm #immunobiologyandimmunotherapy

[Pediatric Transplantation @pedtransjrnl]

10.1111/petr.14390

Metronidazole for treatment of norovirus in pediatric transplant recipients

https://t.co/TwDA5duQ0w

[Venky @venkymd]

📖 Our multi-centre study:
2 drug vs 3 drug induction in pediatric acute myeloid leukemia
https://t.co/D1Gieq0wVN
✅ No benefit in survival with addition of 3rd drug etoposide (ADE) to dauno and ARAC (3+7)
✅ Similar toxicities
✅ First INPHOG RCT
✅ First RCT on AML from LMIC

[ALL Hub @ALL_Hub_]

KEY POINTS:
▪️ CCR9 is highly expressed in patients with T-ALL, including R/R T-ALL.
▪️ Anti-CCR9 CAR T cells show potent in vitro & in vivo antileukemic activity and resistance to fratricide, suggesting they could be an effective treatment.
#ALLsm
👉 https://t.co/raSG7NHB9V 👈

[Pediatric Cell Therapy @PedCellTx]

@hmgcoa2 We had a patient who had unexplainable fever post hsct for months and finally she was diagnosed with lupus...

[GvHD Hub @gvhd_hub]

Have you read this?
🩺 Is calcineurin inhibitor-free #GvHD prophylaxis superior to Tac + MTX with BM in patients undergoing HLA-matched myeloablative HSCT?
👉 https://t.co/r2SfLNMeUp 👈

[Blood Advances @BloodAdvances]

Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
https://t.co/4I5NX7KBWr #systematicreview #clinicaltrialsandobservations #healthservicesandoutcomes

[Pediatric Cell Therapy @PedCellTx]

@nihardesai7 @MedTweetorials @Torsadepointles @pankti4299 @raghadesai We face several cases post hsct specially in patients with fanconi anemia and thalassemia who recieve calcineurin inhibitors as gvhd prophylaxis... Anybody knows how we could prevent it?!...

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai7]

Hey #medicine residents !!

36, male, c/o B-ALL p/w headache and 1 episode of GTCS on D12 of therapy 😲

What is going on ?

#MedTwitter

[Vera Radici @RadiciVera]

Acute GvHD therapy by Prof.@AttilioOlivieri #ITC22 @TheEBMT @TheEBMT_Trainee

[Vera Radici @RadiciVera]

Dr.@abazarbachi's excellent presentation on early endothelial complications after HCT📍TA-TMA 👏🏻 @TheEBMT @TheEBMT_Trainee

[Akshay Sharma MD @AkshaySharmaMD]

Our paper on #COVID19 in #Pediatric #BMTsm recipients is now in @ASTCT_Journal: Pandemic is still around & while outcomes in childhood HCT survivors are better than adults, there are still avenues for improvement & protecting those who are most vulnerable https://t.co/NATLVWn6Nk

[EBMT @TheEBMT]

📣 Check out this publication in @NLM_NIH📣

📃 Stem Cell Transplantation in Patients Affected by Shwachman-Diamond Syndrome: Expert Consensus and Recommendations From the EBMT Severe Aplastic Anaemia Working Party ⬇️
https://t.co/IN6kWrGeF1

#HSCT #BMTsm #MedTwitter

[TransplantID Journal @TheTxIDjournal]

Manuscript from 🇯🇵: Letermovir associated w/ ⬇️ risk of CMV overall in HCT. In MV analysis, only significant factor associated w/ clinically significant CMV among those on letermovir was HCT from a CMV sero-Neg donor to a sero-Pos recipient #TxID #CMV
https://t.co/vLszn8NLeG

[Journal of Brown Hospital Medicine @BrownJHM]

Anemia overview (Handout from Run The List podcast @runthelistpod) #BJHM #MedEd #FOAMed #anemia #MedTwitter #hemetwitter #Medstudenttwitter

[ALL Hub @ALL_Hub_]

Blinatumomab offers clinically meaningful outcomes when added to prephase and consolidation in newly diagnosed patients with ALL. Find out more, and view our visual abstract here 👇 #leusm #allsm
https://t.co/usaZcrsDUK

[ASH Clinical News @ASHClinicalNews]

A multiethnic study of #pediatric patients with #AcuteLymphoblasticLeukemia found multiple factors were linked to relapse risk, including #MRD status, with 136 MRD-negative patients relapsing compared to 73 MRD-positive patients.